- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT06581146
Een onderzoek om de levergezondheid te controleren bij jongens met XLMTM, een ernstige genetische spieraandoening (EXCEL)
Een niet-interventioneel, epidemiologisch onderzoek naar XLMTM en klinische expressie in de lever
XLMTM (X-linked myotubular myopathy) is a serious genetic muscle condition. It is caused by changes in the MTM1 gene which stops or slows down normal muscle development, causing severe muscle weakness. There is currently no cure for XLMTM. Ongoing care is needed to manage symptoms and prevent further medical problems from this condition.
Recent research shows that individuals with XLMTM often have reduced bile flow which can affect liver and gallbladder health. Bile is a liquid made in the liver that helps digest fat. Ongoing liver health checks may help with the routine care of people with XLMTM.
There is a need to understand liver problems that develop in individuals with XLMTM over time. The main aim of the study is to learn how many boys with XLMTM have new cases of liver problems during the study.
This study is about collecting information only. This is known as an observational study. The individual's doctor decides on treatment, not the study sponsor (Astellas).
In this study, boys under 18 diagnosed with XLMTM will be followed for about 1 year. The health of their liver and gallbladder will be checked about every 6 weeks. This can be done at home, if preferred. A scan called a Fibroscan (also known as transient elastography) will check for signs of scarring in the liver (fibrosis) and the build-up of lipids. It is suggested that each boy will have a Fibroscan when they start the study and another scan when they complete the study.
This study will help understand liver, gallbladder, and bile duct issues in individuals with XLMTM over time. The goal is to improve their care and provide information to use in future clinical studies.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Contacten en locaties
Studiecontact
- Naam: Astellas Gene Therapies
- Telefoonnummer: 800-888-7704
- E-mail: Astellas.registration@astellas.com
Studie Locaties
-
-
Ontario
-
Toronto, Ontario, Canada
- Werving
- Site CA15001
-
-
-
-
-
Leeds, Verenigd Koninkrijk
- Werving
- Site GB44006
-
London, Verenigd Koninkrijk
- Werving
- Site GB44003
-
Oxford, Verenigd Koninkrijk
- Werving
- Site GB44005
-
-
-
-
California
-
Santa Monica, California, Verenigde Staten, 90401-2072
- Werving
- UCLA Neurological Services
-
-
Illinois
-
Chicago, Illinois, Verenigde Staten, 60611
- Werving
- Ann & Robert H. Lurie Children's Hospital of Chicago
-
-
Massachusetts
-
Boston, Massachusetts, Verenigde Staten, 02115
- Werving
- Boston Children's Hospital
-
-
Ohio
-
Cincinnati, Ohio, Verenigde Staten, 45229
- Werving
- Cincinnati Children's Hospital Medical Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Verenigde Staten, 19104
- Werving
- Children's Hospital of Philadelphia
-
Pittsburgh, Pennsylvania, Verenigde Staten, 15224
- Werving
- UPMC Children's Hospital of Pittsburgh
-
-
Utah
-
Salt Lake City, Utah, Verenigde Staten, 84112
- Werving
- University of Utah
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
Approximately 50 male participants < 18 years of age with genetically confirmed XLMTM will be enrolled at specialist sites.
Beschrijving
Inclusion Criteria:
- Participant has a diagnosis of XLMTM resulting from a genetically confirmed mutation in the MTM1 gene based on genetic test reports.
- Participant requires some mechanical ventilatory support (e.g., ranging from 24 hours per day full-time mechanical ventilation, to non-invasive support such as continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BiPAP) during sleeping hours)
- Participant (as applicable) and/or parent(s)/carer is willing to comply with the recommended schedule of assessments.
Exclusion Criteria:
- Participant is currently enrolled in an interventional study designed to treat XLMTM.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Observatiemodellen: COHORT
- Tijdsperspectieven: PROSPECTIVE
Cohorten en interventies
Groep / Cohort |
Interventie / Behandeling |
|---|---|
|
Participants with XLMTM
Pediatric and adolescent participants with XLMTM. |
No investigational drug will be administered to participants in this study. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Incidence rate of cholestasis
Tijdsspanne: Up to Week 48
|
Calculated as the number of new cases of cholestasis over 48 weeks divided by total duration of follow-up for enrolled participants. |
Up to Week 48
|
|
Point prevalence of cholestasis
Tijdsspanne: Day 1
|
Point prevalence of cholestasis is defined as the proportion of participants who have had at least 1 case of cholestasis prior to Day 1 (baseline). |
Day 1
|
|
Prevalence of cholestasis
Tijdsspanne: Up to 1 year
|
Prevalence of cholestasis is defined as the proportion of participants who have had at least 1 case of cholestasis within 1 year of Day 1 (baseline). |
Up to 1 year
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Genetic variants of MTM1
Tijdsspanne: Up to Week 48
|
The association between genetic variants of MTM1 and cholestasis will be evaluated. |
Up to Week 48
|
|
Risk of cholestasis temporarily associated with environmental modifiers
Tijdsspanne: Up to Week 48
|
Medication use, immunization history, infectious disease history and dietary habits will be collected. |
Up to Week 48
|
|
Hospitalizations
Tijdsspanne: Up to Week 48
|
Frequency and reason for hospitalizations will be collected. |
Up to Week 48
|
|
Duration of Hospitalizations
Tijdsspanne: Up to Week 48
|
Duration of hospitalization visits will be collected. |
Up to Week 48
|
|
Emergency room visits
Tijdsspanne: Up to Week 48
|
Frequency and reason for visit will be collected. |
Up to Week 48
|
|
Hepatology specialist visits
Tijdsspanne: Up to Week 48
|
Frequency and reason for visit will be collected. |
Up to Week 48
|
|
Scheduled/unscheduled office visits
Tijdsspanne: Up to Week 48
|
Frequency and reason for visit will be collected. |
Up to Week 48
|
|
Non-study-specified home healthcare visits
Tijdsspanne: Up to Week 48
|
Frequency and reason for visit will be collected. |
Up to Week 48
|
|
Surgeries/procedures
Tijdsspanne: Up to Week 48
|
Frequency and type will be collected. |
Up to Week 48
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Studie directeur: Medical Director, Astellas Gene Therapies
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 1600-MA-3536
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .